

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following Grade 3 adverse events was most commonly reported by patients receiving capivasertib for previously treated HR-positive, HER2-negative advanced breast cancer on the Phase III CAPItello-291 study?
 - Infection
 - Rash
 - Hyperphosphatemia
 - Blurred vision
- What was the approximate reduction in the risk of disease progression or death with inavolisib for patients with HR-positive, HER2-negative advanced breast cancer with PIK3CA mutation in the Phase III INAVO120 trial?
 - 11%
 - 22%
 - 57%
 - 79%
- Patritumab deruxtecan targets which of the following proteins?
 - HER2
 - HER3
 - LIV1A
 - TROP2
- Which of the following results best describes progression-free survival (PFS) outcomes with elacestrant compared to standard endocrine therapy for patients with ER-positive, HER2-negative advanced breast cancer in the Phase III EMERALD trial?
 - No improvement in PFS across subgroups
 - PFS improvement for patients with ESR1 mutations and bone metastases
 - PFS improvement for patients with ESR1 mutations and either TP53 or PIK3CA mutations
 - PFS improvement for all patients with ESR1 mutations
- Which of the following patients with HR-positive, HER2-negative localized breast cancer derived an invasive disease-free survival (iDFS) benefit with adjuvant ribociclib in combination with endocrine therapy according to final iDFS analysis of the Phase III NATALEE trial?
 - Patients with node-negative disease
 - Patients with node-positive disease
 - Both a and b
 - Neither a nor b